Yukihiko Saeki

Yukihiko Saeki

Auto-generated profile, based on publicly available information

Yukihiko Saeki

National Hospital Organization Osaka-Minami Medical Center, Osaka, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2003 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
TYToru Saeki Mima Yukihiko
Toru Saeki Mima Yukihiko
TITaeko Ishii
Taeko Ishii
AOAtsushi Ogata
Atsushi Ogata
HKHideyuki Kobayashi
Hideyuki Kobayashi
SOShiro Ohshima
Shiro Ohshima
IKIchiro Kawase
Ichiro Kawase

1 October 2002
Verified
Journal Article
Closed access
SOShiro Ohshima
Shiro Ohshima
NYNorihiko Yamaguchi
Norihiko Yamaguchi
KNKatsuhiro Nishioka
Katsuhiro Nishioka
TMToru Mima
Toru Mima
TITaeko Ishii
Taeko Ishii
YSYukihiko Saeki
Yukihiko Saeki

1 January 2003
Verified
Journal Article
Closed access
NYNorihiko Yamaguchi
Norihiko Yamaguchi
SOShiro Ohshima
Shiro Ohshima
MUMitsuko Umeshita-Sasai
Mitsuko Umeshita-Sasai
KNKatsuhiro Nishioka
Katsuhiro Nishioka
HKHideyuki Kobayashi
Hideyuki Kobayashi
YSYukihiko Saeki
Yukihiko Saeki

3 May 2013 in Modern Rheumatology
Verified
Journal Article
Closed access
PDF file
NNNorihiro Nishimoto
Norihiro Nishimoto
KAKoichi Amano
Koichi Amano
YHYasuhiko Hirabayashi
Yasuhiko Hirabayashi
THTakahiko Horiuchi
Takahiko Horiuchi
TITomonori Ishii
Tomonori Ishii
NTNobuhiro Takagi
Nobuhiro Takagi
To investigate the duration of remission and low disease activity (LDA) after cessation of tocilizumab (TCZ) treatment in rheumatoid arthritis patients who showed remission or LDA as assessed by DAS28 in response to preceding TCZ monotherapy, and to explore the factors contributing to prolonged efficacy duration.

1 June 2002
Verified
Journal Article
Closed access
HKHideyuki Kobayashi
Hideyuki Kobayashi
SOShiro Ohshima
Shiro Ohshima
KNKatsuhiro Nishioka
Katsuhiro Nishioka
NYNorihiko Yamaguchi
Norihiko Yamaguchi
MUMitsuko Umeshita-Sasai
Mitsuko Umeshita-Sasai
YSYukihiko Saeki
Yukihiko Saeki

2 October 2010 in Modern Rheumatology
Verified
Journal Article
Closed access
PDF file
TITaeko Ishii
Taeko Ishii
YKYoshinori Katada
Yoshinori Katada
YSYukihiko Saeki
Yukihiko Saeki
Spontaneous perirenal hematoma (SPH) is a rare, life-threatening condition. We present a patient with Wegener’s granulomatosis (WG) who developed SPH soon after the initiation of immunosuppressant therapy. Few cases of SPH as a complication of WG have been reported, though a rupture of an aneurysm in patients with polyarteritis nodosa can lead to SPH. Though immunosuppressant therapy is considered to be the first-line therapy for SPH with vasculitis, SPH could still occur after the initiation of an adequate treatment regimen.